Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Celgene MEDI4736-MM-001: A Phase 1B Multicenter, Open-Label Study to Determine the Recommended Dose and Regimen of Durvalumab (MEDI4736) Either as Monotherapy or in Combination with Pomalidomide (POM) with or without Low Dose Dexamethasone (DEX) in Subje
Brief Description  
Primary: To determine the recommended dose and regimen of durvalumab as monotherapy or in combination with POM +/- dex in subjects with RRMM. Secondary: 1) To evaluate the safety and preliminary efficacy of durvalumab monotherapy and in combination with POM +/- dex in subjects with RRMM 2) To evaluate the pharmacokinetics (PK) of DUR and POM with or without dexamethasone in subjects with RRMM Exploratory: 1) To determine the immunogenicity of durvalumab as single agent and when given in comb
Who may be Eligible  
Please contact us for eligibility criteria.
Multiple Myeloma
Start Date  
IRB Number  
Principal Investigator  
Usmani, Saad Zafar
Contact Name  
Carolyn Lehman

For More Information, Contact  Carolyn  , Lehman
Phone:  980-442-5225 Fax:    
Email:  Carolyn.Lehman@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204